Neem oil in psoriasis vulgaris

Investigating the effects of neem oil (Azadirachta Indica)in improving the skin manifestations of psoriasis vulgaris patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20260215068870N1

Enrollment

Registered

2026-04-22

Start date

2026-04-20

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis vulgaris. Psoriasis vulgaris

Interventions

Intervention 1: Intervention group: Patients in this group, in addition to standard treatment (topical betamethasone 0.05% corticosteroid), use pure neem oil (Azadirachta Indica) once daily topically

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Adults (18 years or older) diagnosed with psoriasis vulgaris Patients with mild to moderate psoriasis

Exclusion criteria

Exclusion criteria: Presence of other skin diseases Nail involvement in psoriasis Use of neuropsychiatric medications such as lithium or drugs like beta-blockers and hydroxychloroquine Concurrent use of systemic or biological treatments for psoriasis Presence of other significant skin diseases Known allergies or sensitivities to neem oil

Design outcomes

Primary

Measure	Time frame
Psoriasis Area and Severity Index (PASI). Timepoint: Three time points: 1-Before treatment initiation (Baseline) 2-One month after treatment start 3-Two months after treatment start. Method of measurement: Clinical assessment by a dermatologist using the standard PASI index form. Scoring is based on four body regions (head/neck, trunk, upper extremities, lower extremities) and three parameters (erythema, induration, scaling) considering the percentage of involved area.;Dermatology Life Quality Index (DLQI). Timepoint: Three time points: 1-Before treatment initiation (Baseline) 2-One month after treatment start 3-Two months after treatment start. Method of measurement: Completion of the standard DLQI questionnaire by the patient. Each question has 4 responses (0-3) with a maximum total score of 30. Higher scores indicate lower quality of life.;Patient's satisfaction level. Timepoint: Three time points: 1-Before treatment initiation (Baseline) 2-One month after treatment start 3-Two months after treatment start. Method of measurement: Using a 5-point Likert scale:1 = Completely dissatisfied2 = Dissatisfied3 = Neutral4 = Satisfied5 = Completely satisfied.	—

Measure

Time frame

Psoriasis Area and Severity Index (PASI). Timepoint: Three time points: 1-Before treatment initiation (Baseline) 2-One month after treatment start 3-Two months after treatment start. Method of measurement: Clinical assessment by a dermatologist using the standard PASI index form. Scoring is based on four body regions (head/neck, trunk, upper extremities, lower extremities) and three parameters (erythema, induration, scaling) considering the percentage of involved area.;Dermatology Life Quality Index (DLQI). Timepoint: Three time points: 1-Before treatment initiation (Baseline) 2-One month after treatment start 3-Two months after treatment start. Method of measurement: Completion of the standard DLQI questionnaire by the patient. Each question has 4 responses (0-3) with a maximum total score of 30. Higher scores indicate lower quality of life.;Patient's satisfaction level. Timepoint: Three time points: 1-Before treatment initiation (Baseline) 2-One month after treatment start 3-Two months after treatment start. Method of measurement: Using a 5-point Likert scale:1 = Completely dissatisfied2 = Dissatisfied3 = Neutral4 = Satisfied5 = Completely satisfied.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Majid Shohrati

Bagheiat-allah University of Medical Sciences

majidshohrati@gmail.com+98 917 228 2616

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026